CureVac GmbH - Product Pipeline Review - 2016

  • ID: 3720454
  • Company Profile
  • 49 pages
  • Global Markets Direct
1 of 4
CureVac GmbH - Product Pipeline Review - 2016

Summary

‘CureVac GmbH - Product Pipeline Review - 2016’, provides an overview of the CureVac GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CureVac GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of CureVac GmbH
- The report provides overview of CureVac GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses CureVac GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features CureVac GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate CureVac GmbH’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for CureVac GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CureVac GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

CureVac GmbH Snapshot

CureVac GmbH Overview

Key Information

Key Facts

CureVac GmbH - Research and Development Overview

Key Therapeutic Areas

CureVac GmbH - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

CureVac GmbH - Pipeline Products Glance

CureVac GmbH - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

CureVac GmbH - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

CureVac GmbH - Drug Profiles

CV-9104

Product Description

Mechanism of Action

R&D Progress

CV-9103

Product Description

Mechanism of Action

R&D Progress

CV-9201

Product Description

Mechanism of Action

R&D Progress

CV-8102

Product Description

Mechanism of Action

R&D Progress

nadorameran

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Cancer

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Infectious Disease

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Influenza Virus Infection

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for respiratory syncytial virus vaccine

Product Description

Mechanism of Action

R&D Progress

infectious disease vaccine

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for HIV

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Respiratory Syncytial Virus-1 Infection

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Rotavirus Infection

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Oligonucleotides for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Vaccine 1 for oncology

Product Description

Mechanism of Action

R&D Progress

Vaccine for Oncology

Product Description

Mechanism of Action

R&D Progress

CureVac GmbH - Pipeline Analysis

CureVac GmbH - Pipeline Products by Target

CureVac GmbH - Pipeline Products by Route of Administration

CureVac GmbH - Pipeline Products by Molecule Type

CureVac GmbH - Recent Pipeline Updates

CureVac GmbH - Dormant Projects

CureVac GmbH - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

CureVac GmbH, Key Information

CureVac GmbH, Key Facts

CureVac GmbH - Pipeline by Indication, 2016

CureVac GmbH - Pipeline by Stage of Development, 2016

CureVac GmbH - Monotherapy Products in Pipeline, 2016

CureVac GmbH - Partnered Products in Pipeline, 2016

CureVac GmbH - Partnered Products/ Combination Treatment Modalities, 2016

CureVac GmbH - Out-Licensed Products in Pipeline, 2016

CureVac GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016

CureVac GmbH - Phase II, 2016

CureVac GmbH - Phase I, 2016

CureVac GmbH - Preclinical, 2016

CureVac GmbH - Discovery, 2016

CureVac GmbH - Pipeline by Target, 2016

CureVac GmbH - Pipeline by Route of Administration, 2016

CureVac GmbH - Pipeline by Molecule Type, 2016

CureVac GmbH - Recent Pipeline Updates, 2016

CureVac GmbH - Dormant Developmental Projects,2016

CureVac GmbH, Other Locations

List of Figures

CureVac GmbH - Pipeline by Top 10 Indication, 2016

CureVac GmbH - Pipeline by Stage of Development, 2016

CureVac GmbH - Monotherapy Products in Pipeline, 2016

CureVac GmbH - Out-Licensed Products in Pipeline, 2016

CureVac GmbH - Pipeline by Top 10 Target, 2016

CureVac GmbH - Pipeline by Route of Administration, 2016

CureVac GmbH - Pipeline by Molecule Type, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll